M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy. - Wikidata - awgldk - TriplyDB

M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy.

M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy.

http://www.wikidata.org/entity/Q35538840

about

Facilitation of hippocampal synaptogenesis and spatial memory by C-terminal truncated Nle1-angiotensin IV analogs Trafficking regulation of proteins in Alzheimer's disease Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders.Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents.The M3-muscarinic receptor regulates learning and memory in a receptor phosphorylation/arrestin-dependent manner Cholinesterase inhibitors may increase phosphorylated tau in Alzheimer's disease.Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study.GRK5 deficiency accelerates {beta}-amyloid accumulation in Tg2576 mice via impaired cholinergic activity.Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function.In vivo regulation of GSK3 phosphorylation by cholinergic and NMDA receptors.Hippocampal M1 receptor function associated with spatial learning and memory in aged female rhesus macaques.Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder Age-associated learning and memory deficits in two mouse versions of the Stone T-maze.Acetylcholinesterase inhibitors for the treatment of dementia in Alzheimer's disease: do we need new inhibitors?Role of melatonin in Alzheimer-like neurodegeneration.Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease.Donepezil: a review.Inactivation of JAK2/STAT3 signaling axis and downregulation of M1 mAChR cause cognitive impairment in klotho mutant mice, a genetic model of aging Melatonin in Alzheimer's disease The PI3K-Akt-mTOR pathway regulates Abeta oligomer induced neuronal cell cycle events.Current and future therapy in Alzheimer's disease.Current therapeutic targets for the treatment of Alzheimer's disease.Current perspectives on pharmacotherapy of Alzheimer's disease.In vitro safety pharmacology profiling: what else beyond hERG?Cholinergic System and Post-translational Modifications: An Insight on the Role in Alzheimer's Disease Novel N-Substituted Benzimidazolones as Potent, Selective, CNS-Penetrant, and Orally Active M1 mAChR Agonists.Progress in the development of new drugs in Alzheimer's disease.Deficit in learning and memory of rats with chronic fluorosis correlates with the decreased expressions of M1 and M3 muscarinic acetylcholine receptors.Identification of multiple allosteric sites on the M1 muscarinic acetylcholine receptor.Population-based study suggests an increased risk of Alzheimer'sdisease in Sjögren's syndrome.Interpreting the structural mechanism of action for MT7 and human muscarinic acetylcholine receptor 1 complex by modeling protein-protein interaction.Pharmacological effects of Ibuprofen on learning and memory, muscarinic receptors gene expression and APP isoforms level in pre-frontal cortex of AlCl₃-induced toxicity mouse model.Muscarinic receptor dependent long-term depression in rat visual cortex is PKC independent but requires ERK1/2 activation and protein synthesis.A Photoswitchable Dualsteric Ligand Controlling Receptor Efficacy.L-Satropane Prevents Retinal Neuron Damage by Attenuating Cell Apoptosis and Aβ Production via Activation of M1 Muscarinic Acetylcholine Receptor.High-energy compounds promote physiological processing of Alzheimer's amyloid-β precursor protein and boost cell survival in culture.M1 muscarinic acetylcholine receptor agonism alters sleep without affecting memory consolidation.Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma 1 (σ1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative.The snake venom peptide Bj-PRO-7a is a M1 muscarinic acetylcholine receptor agonist.Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease.

P2860

Q24635261-1BDB6229-FD60-420F-A42C-49E84E11C906 Q26825722-2E55D0AF-B498-4662-8ABA-759C638EE1D8 Q30388923-BF91D31E-530F-45A8-8F5D-774D8074B647 Q30530935-358BEA14-1202-4BD7-8FDB-69D4D446A635 Q33927277-8FD46025-B46A-4BB8-9095-EECD234756F2 Q33998388-0F506DA4-D1A5-41C4-A563-7EB4E6CD235A Q34104256-BEB5A3F8-8D9C-42D6-A697-7232A40DB977 Q34438832-EB44ACC4-5DC4-4C2F-898B-6CB1E43F0A7E Q34552778-C1491A56-E86B-45FF-9CB5-1C22BD8F446F Q35103820-DA89BA4A-F67D-4085-8FB0-768595F82A7B Q35201147-8F5A33DF-3059-4CAB-9CF4-0FA59382FD65 Q35546189-5BFDC92B-D53C-4ED9-B230-954F3D0E729A Q35875514-210648F5-6768-41F2-8154-8417B4F12A4E Q36302845-A7F2154B-FBAB-4D64-8091-3C29B1CD2C07 Q36346522-E7EA2DC2-43EF-4506-B260-65CBE1CB1D0E Q36401406-D82F41C9-F960-4677-A1CF-613FED23F909 Q36544994-2C5330E5-8531-46CB-85F2-DFF227F5CE66 Q36927714-F211A0EE-2AF7-4834-910C-956F9A0AFAD9 Q37091982-72CF8F09-5EC1-4F35-BBFF-C2E4688D470B Q37145922-C4B01784-DB27-4C69-A5B5-BAABCAD78CE7 Q37165703-227AAE71-B633-4FD7-B90F-BF563EC85754 Q37737296-C427ABBC-1A2D-46F0-8001-3E46FDDC6860 Q37827489-F866AA0F-7CAD-4C96-98BF-7AAA69762BD8 Q37855844-B342D660-3AB2-4E21-B256-9E6125E7789C Q38788038-ED66ACE0-9026-4F02-AB2F-1926D538FCEB Q39155961-0E537004-BC6E-4117-849F-4314464D1E33 Q39789745-826D6E75-647B-4522-96F4-38008FD2C0BC Q42703574-6F92EFC4-8AE2-4C6C-9946-BD368B14F8C1 Q46822777-BF9C3F78-0468-4206-8430-546BBB84E2E5 Q47306169-D4DF6CE7-BE72-49B0-ABA3-979EB1F79689 Q47788379-C59E0E86-1BD1-4659-9EE4-94D52CEBF2ED Q47876298-AA02E031-08D7-404C-969E-02BD5151B53E Q48103250-CB03539B-2E10-4EC0-9042-612CDEF0315F Q48136609-0714AFEF-ADE9-42E5-9D46-7C9F42A54D0C Q48250501-87C66D46-FA76-495A-B19E-1D3DF13C3090 Q48404424-3A43E546-E5DF-4DFD-A707-695B5E7DBB21 Q48486682-7D1D7996-DF52-4C88-840C-856268171590 Q51037995-67180FAF-D4C4-4248-8D97-63F3B4CC5335 Q51771947-FDCBAF17-BF01-4C8A-8C6D-8B300192CCE0 Q55405667-7C156A8D-14F6-4640-A06D-FCB6D0CC7AA3

P2860

M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy.

http://www.wikidata.org/entity/Q35538840

description

2003 nî lūn-bûn

@nan

2003 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

M1 muscarinic agonists can mod ...... mplications in future therapy.

@ast

M1 muscarinic agonists can mod ...... mplications in future therapy.

@en

type

label

M1 muscarinic agonists can mod ...... mplications in future therapy.

@ast

M1 muscarinic agonists can mod ...... mplications in future therapy.

@en

prefLabel

M1 muscarinic agonists can mod ...... mplications in future therapy.

@ast

M1 muscarinic agonists can mod ...... mplications in future therapy.

@en

P1433

Q35538840-5DD3B408-2494-4C46-BE56-452719C0F6CE

P1476

Q35538840-CCAB1374-1ED6-42E6-A820-2368612FF726

P2093

Q35538840-19610AB2-C39D-4FEF-AD16-FF9B82C853E0

Q35538840-23363A9F-CB8D-4F03-BEBE-3B9762F1F91F

Q35538840-28624067-F966-429D-BA38-3EF7E3A648F8

Q35538840-355679B3-9D42-44CD-BAA4-59A189521F2F

Q35538840-66EAA998-5E7E-40B4-AEA6-ADF26E26B02D

Q35538840-6F2699E6-8A1F-4129-A73C-B974F7461F7B

Q35538840-771F7196-9FA6-43A5-B1F6-E6E148D96811

Q35538840-779F8EB3-DCF4-45EE-8687-7C93125669D4

Q35538840-B1E1ECB3-26CF-4C81-8540-6F9CA8273C8A

Q35538840-E753F792-D47D-4A16-8EB2-ACDEF45381A6

P2888

Q35538840-3B84015A-6D53-4352-9A3C-280A1FBF8E88

P304

Q35538840-3D0A6B9C-0AA3-47EE-8598-A24CA7E68E4E

P31

Q35538840-B5B8393A-2B6F-4AB8-A68A-2FA5D1E24F3B

P356

Q35538840-F9B0D97F-0D98-4574-A179-14150AE9FF25

P433

Q35538840-EB9FC5C5-081D-4445-839F-152AC6028820

P478

Q35538840-D8D68BFD-9661-4144-9B46-109B0D51E342

P577

Q35538840-D0A0CEC6-0234-4802-8FE9-59550381D340

P6179

Q35538840-8853689F-DA5D-4A1D-A69D-BB30F690568D

P698

Q35538840-8125BEEF-73B5-40F5-9017-03F3D5074A5B

P921

Q35538840-681F8DE7-0EF1-47BF-8343-80BE5E6382D5

P356

P1433

Journal of Molecular Neuroscience

P1476

M1 muscarinic agonists can mod ...... mplications in future therapy.

@en

P2093

Abraham Fisher

http://www.w3.org/2001/XMLSchema#string

Hagar Sonego

http://www.w3.org/2001/XMLSchema#string

Inbal Egozi

http://www.w3.org/2001/XMLSchema#string

Itzhak Marcovitch

http://www.w3.org/2001/XMLSchema#string

Michal Kliger-Spatz

http://www.w3.org/2001/XMLSchema#string

Nira Bar-Ner

http://www.w3.org/2001/XMLSchema#string

Niva Natan

http://www.w3.org/2001/XMLSchema#string

Rachel Brandeis

http://www.w3.org/2001/XMLSchema#string

Rachel Haring

http://www.w3.org/2001/XMLSchema#string

Zipora Pittel

http://www.w3.org/2001/XMLSchema#string

P2888

P304

349-356

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1385/JMN:20:3:349

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2003-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1026532374

http://www.w3.org/2001/XMLSchema#string

P698

14501019

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease